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Abstract 
 
Introduction: In January 2018 the European Commission published a Proposal for a Regulation on 
Health Technology Assessment (HTA): ‘Proposal for a Regulation on health technology assessment 
and amending Directive 2011/24/EU’. A number of stakeholders, including some Member States, 
welcomed this initiative as it was considered to improve collaboration, reduce duplication and improve 
efficiency; there were however a number of concerns including its legal basis, the establishment of a 
single managing authority, the preservation of national jurisdiction over HTA decision making and the 
voluntary/mandatory uptake of joint assessments by Member States.  Areas covered: This paper 
presents the consolidated views and considerations on the original Proposal as set by the European 
Commission of a number of policy makers, payers, experts from pricing and reimbursement 
authorities and academics from across Europe.  Expert commentary: The Proposal has since been 
extensively discussed at Council and while good progress has been achieved, there are still divergent 
positions. The European Parliament gave a number of recommendations for amendments. If the 
Proposal is approved, it is important that balanced, improved outcome is achieved for all 
stakeholders. If not approved, the extensive contribution and progress attained should be sustained 
and preserved, and the best alternative solutions found. 
 
Key words: EUnetHTA; joint collaboration on HTA; cross border agreements; Member States; 
European legislation 
 
1. Introduction 
 
This paper presents the consolidated views and considerations of a number of policy makers, payers, 
experts from pricing and reimbursement authorities as well as academics from across Europe 
regarding the ‘Proposal for a Regulation on health technology assessment and amending Directive 
2011/24/EU’ hereafter referred to as the ‘Proposal’. For the purpose of this paper, “payers” refer to 
those persons and institutions responsible for public financing of healthcare, including reimbursement 
decisions, such as social insurances, government agencies or health authorities. We are aware that 
whilst several groups of payers (AIM Association Internationale de Mutualite;  ESIP - European Social 
Insurance Platform and MEDEV - Medicines evaluation Committee) have been discussing the 
Proposal [1-3], there currently appears no consolidated view from payers and their advisers from 
across Europe to enhance future discussions as this important initiative evolves. The contributing 
authors come from different Member States and from different bodies and institutions.  
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This paper was based on the original Proposal before the discussions in the Council and the 
European Parliament took place. When the Proposal was published, the potential multifaceted impact 
of the Proposal and its deliberations on the future health technology assessment (HTA) and policies 
among EU Member States and their citizens, brought about an urgent need to analyse and discuss 
the strengths and concerns of the Proposal, as well as possible alternative considerations to stimulate 
ongoing debates now and in the future. By the time this review paper is published, the discussions at 
the Council and Parliament will have progressed significantly. We are also aware that there have 
been, and still are ongoing, detailed discussions of the Proposal and changes are under 
consideration. There have also been debates at the European Parliament’s Committee on the 
Environment, Public Health and Food Safety (ENVI) on the Proposal [4,5], and amendments were 
adopted at the Parliament Plenary on the 3rd of October 2018. A number of the points brought up by 
the authors in this paper were discussed, debated, and also proposed for amendments during the 
discussions at the European Parliament as well as the Council. This paper will not go into the details 
of the recommendations and the discussions from this debate. In spite of the progress being achieved 
in the co-legislative process, the discussion and the updates are still ongoing; consequently, we 
believe the publication of this paper is still relevant.  
 
While the Proposal covered HTA for different modalities including medicinal products, medical 
devices and in-vitro diagnostics this paper will focus mainly on HTA for medicinal products.  
 
2. The current EU legislative framework 
 
HTA, pricing and reimbursement of medicinal products, which incorporate both clinical and economic 
aspects of technologies [6,7], are established on the basis of Article 168 of the Treaty of the 
Functioning of the European Union (TFEU), and are within the competence of Member States. Article 
5(2) of the TFEU sets the principles of conferral (which governs the limits of EU competences) and 
the principle of subsidiarity whereby the EU does not take action (except in the areas that fall within its 
exclusive competence) unless it is more effective than action taken at the national level. The 
European Union, the European Parliament, and the Council, can adopt measures for setting high 
standards of quality and safety for medicinal products. The TFEU specifies that it is fully the 
competence and responsibility of Member States to decide which medicinal products are reimbursed 
and at what price [8,9]. The Treaties mandate the European Commission to encourage cooperation 
between Member States in the field of public health and, if necessary, lend support to their actions. 
According to Article 6 of the TFEU, in the field of protection and improvement of human health, the 
Union has the competence to carry out activities aimed at supporting, coordinating or supplementing 
the actions of Member States. The Union's competences do not replace the States’ competence in 
this area, and EU acts must not lead to harmonization of the Member States' laws and regulations 
(Article 2 (5) TFEU).  
 
Pricing and reimbursement are regulated by the ‘Transparency Directive’ (Directive 89/105/EEC). This 
Directive lies at the interface between EU responsibilities for the internal market and national 
competences in the area of public health in accordance with Article 168(7) of the TFEU. Its provisions 
affect national policies on price setting and the organisation of social security schemes just as far as it 
is necessary to achieve transparency. In March 2013, the European Commission adopted an 
amended proposal to amend this Directive but the amendment was officially withdrawn in March 2015 
[10]. 
 
3. Historical background on initiatives for HTA 
 
For over 20 years, there have been various initiatives to strengthen collaboration on HTA across 
Europe. This started with the EUR-ASSESS project funded by the European Commission during 
1994-1996 [11]. This project aimed to promote coordination of HTA in Europe by improving methods 
of assessment, priority setting, and the use of HTA results through better dissemination and use of 
HTA in coverage decisions. Thereafter, two other research projects were funded by the European 
Commission to improve collaboration between HTA institutions in Europe. These were HTA Europe 
(1997–1999) and the ECHTA/ECHAHI (European Collaboration for Assessment of Health 
Interventions) project (1999–2001) [11,12]. These projects laid the foundation for the European 
Network for Health Technology Assessment (EUnetHTA). EUnetHTA is a network of government 
appointed organisations combined with a large number of regional agencies and not for profit 
organisations. The first EUnetHTA project (2006 – 2008) was followed by the EUnetHTA 
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Collaboration (2009) [11,13]. This was followed by three EU Joint Action projects JA1 (2010-2012), 
JA2 (2012-2015) and the ongoing JA3(2016-2020) [13,14]. The main objectives of EUnetHTA 
included support of the efficient production and use of HTA in decision making across Europe, 
provision of an independent and science-based platform, an access point for communication and the 
development of research. Over the last three years, Member States have also developed regional co-
operations, e.g. BeNeLuxAIr, the Valletta Declaration, FINOSE and Visegrad projects, to undertake 
joint activities such as HTA,price negotiations especially for new medicines for orphan diseases, 
horizon scanning and information sharing [15-18].  
 
The Health Technology Assessment Network (HTA Network) was established by the European 
Commission in line with Article 15 of Directive 2011/24/EU. This Network includes a representative 
from all EU countries and aims to (i) support cooperation between national authorities or bodies, 
(ii) support Member States in the provision of objective, reliable, timely, transparent, comparable and 
transferable information on the relative efficacy as well as on the short- and long-term effectiveness, 
when applicable, of health technologies, (iii) enable an effective exchange of this information; (iv) 
support the analysis of the nature and type of information that can be exchanged; and (v) avoid 
duplication. The first meeting of the Network took place in October 2013 [19]. In 2014, the HTA 
Network published its strategy for EU cooperation on HTA [20]. The report supported cooperation on 
HTA between Member States, Iceland, and Norway, and presented possibilities for this cooperation 
without being specific on any particular methodology. This strategy was totally based on the principle 
of voluntary cooperation [20]. The Council Conclusions of different Presidencies of the Council of the 
European Union advocated for voluntary cooperation on HTA. The conclusions consider cooperation 
between groups of Member States that share common interests in relation to pricing and 
reimbursement, support exchange of HTA methodologies and assessment of outcomes as well as 
voluntary cooperation to improve access to health technologies [8,21].   
 
In 2016, the European Commission embarked on an initiative to strengthen EU cooperation on HTA 
beyond 2020 since in 2020, the current EU funding from the EU Health Programme 2014 – 2020 will 
end and no permanent funding can subsequently be established according to EU Financial 
Regulations. This initiative adopted the process for Commission Better Regulation [22]. The 
Commission claimed that this initiative was undertaken in response to calls from Member States, the 
European Parliament, and other key stakeholders, to ensure the sustainability of EU HTA beyond 
2020, .It was intended to address the shortcomings identified by the Commission with regards to 
EUnetHTA, i.e. low uptake of joint assessments, differences in HTA frameworks and differences in 
technical capacities among the Member States, significant differences in national HTA methodologies 
and the lack of financial sustainability of the current model of HTA cooperation at the EU level [23]. 
 
In September 2016, the Commission published an Inception Impact Assessment for Strengthening of 
the EU cooperation on HTA. This Impact Assessment defined HTA on the basis of the EUnetHTA 
Core Model in terms of ‘core domains’ [24]. These included a Relative Effectiveness Assessment 
(REA) covering the health problem and the current use of a given technology incorporating its safety 
and clinical effectiveness, as well as ‘other domains’ including costs, an economic evaluation, ethical 
analysis, organisational aspects, patient and social aspects, as well as legal aspects. The Impact 
Assessment specifically excluded pricing and reimbursement decisions, which were considered ‘of 
national prerogative‘; however, quoted studies which demonstrated the potential benefits from HTA 
[25]. In October 2016, the European Commission issued a public consultation, with meetings also 
held with key stakeholders. The public consultation presented different options for HTA which 
considered outputs (voluntary or mandatory participation and uptake), different models of 
implementation (level of EU input and input from an EU agency – existing or new) as well as potential 
funding mechanisms and scope. The responses of the public consultation were published by the 
European Commission. An Impact Assessment was published by the Commission later in 2017 [23].  
 
On the 31st of January 2018, the European Commission issued a legislative proposal: Proposal for a 
Regulation of the European Parliament and of the Council on health technology assessment and 
amending Directive 2011/24/EU [26]. During 2018, the Proposal was discussed by the co-legislators: 
the Council and the European Parliament. ENVI published a draft report and put forward more than 
170 amendments to the Proposal [5]. The Parliament Plenary adopted the amendments on the 3rd of 
October 2018 and referred the proposal back to ENVI. By the end of 2018 the Proposal was still being 
discussed at the Council. The current discussions at the European Parliament and the Council have 
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managed to achieve an agreed position on a number of aspects, although there are still contentions 
over other aspects of the Proposal and the final approval has not yet been achieved. 
 
4. Consolidation of the opinions of the authors on the original Proposal as set by the European 
Commission 
 
As mentioned above, this consolidation of opinions concerned the original Proposal as set by the 
European Commission and took place before the Proposal started being discussed by the co-
legislators. There have been divergent opinions on different aspects of the Proposal. This section 
reflects the different opinions of the authors. These are not in any way linked to the position of the 
different Member States as being expressed at Council.  
 
The Proposal suggested a framework for joint HTA assessment for different health technologies 
including medicinal products and medical devices. For the scope of this section only medicinal 
products will be considered. In the case of medicinal products, the Proposal covers only Relative 
Effectiveness Assessment (REA) for new centrally authorised medicinal products. 
 
It is recognised that there are currently differences in access to medicines for patients across Europe 
as seen with medicines for cancer and orphan diseases [27-31]. This goes against the EU principles 
that all patients within the EU should have a right to equal access to medicines. Some stakeholders 
consider that the Proposal will increase access to medicines, particularly in those countries with low 
access. In a number of countries, the major reasons for differences in access and availability are 
issues of affordability, especially for new biological medicines [32,33]. The Proposal does not address 
prices of medicines and affordability as these are within the competence of each Member State. 
Another concern with access to new medicinal products is the lack or delay by marketing 
authorisation holders to place new medicinal products onto the market of individual Member States. 
This issue is also not addressed by the Proposal. For this hurdle to be overcome, the Proposal should 
oblige the marketing authorisation holder to place the product on the market in all Member States who 
decide to reimburse the product without delay.  
 
In principle, a number of stakeholders, including Member States, support the concept of collaboration 
on HTA, as this is considered to ensure that all countries benefit from HTA conducted in accordance 
with an agreed standard and high level methodology. Countries have different levels of capacity for 
HTA and adopt different models for its utilisation. Some countries have adopted a ‘heavy’ model 
whereby analyses are largely carried out by the national HTA agency, whilst others utilise a ‘light’ 
model whereby the national HTA agency mainly evaluates HTA analyses supplied by the 
pharmaceutical industry for pricing and reimbursement considerations. Some countries apply mixed 
models. The skills needed for HTA should include critical review of the clinical and economic data 
behind the models used to determine the cost-effectiveness of different technologies. Some Member 
States have not yet made use of HTA in their pricing and reimbursement decisions to the same extent 
as others, for example, they mainly base pricing decisions on the perceived level of innovation of the 
new medicine [34-37]. The experience of EUnetHTA has led to the development of tools and 
methodologies for HTA. These will allow joint assessment using agreed methodologies. The Member 
States with limited resources, systems and expertise for HTA are considered to benefit most from joint 
assessment.  
 
Member States acknowledge the challenges posed by the different methodologies, tools, and models 
used for the utilisation of HTA across countries, and generally consider the standardisation of 
approaches positively. Currently, there are different HTA requirements across countries and any REA 
undertaken by EUnetHTA may be considered of limited relevance in certain countries which have 
their national methodology for HTA. Having a joint submission and assessment could potentially 
address this. Joint assessment can be accompanied by different demand-side measures in each 
pertinent Member State to ensure that new medicines are only prescribed in those patients where 
their value is greatest in that country, with usage subsequently monitored [36,38-40], which could also 
be part of any managed entry agreement (MEA) [41-43].  
 
Benefits of HTA collaboration include unification and implementation of common criteria for Member 
States and companies, streamlining of activities, avoidance of duplication, more effective use of 
resources through the development of joint methodologies, synergies between experts and the 
authorities, availability of best expertise to cover future challenges, the possibility of having a common 
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framework to support the process and the possibility of one joint submission [44]. The establishment 
of a joint HTA organisation can bring about improvements in methodologies and scientific standards, 
particularly with increased expertise and specialisation requirements for new medicines [44]. It is 
important that any HTA is undertaken by competent experts, and that the various HTA agencies can 
trust the work and competence of each other. Proposals for collaboration should preserve best 
practices and well-functioning solutions, which have been developed through collaborations across 
Europe since the early nineties as well as in some Member States [7,45]. There could also be benefits 
through possible funding of joint research projects, payment for assessment work as well as for 
consultation and expert advice. Some reimbursement authorities, and possibly also some individuals, 
may see the Proposal as a possible avenue for further specialisation in specific areas of HTA. Current 
models for HTA utilisation in many national healthcare systems have provided a positive and 
stimulating impact on the development of HTA as a relatively new and interdisciplinary science, and 
this should continue. 
 
The Proposal addresses the problem of variable access to clinical data from the marketing 
authorisation submission to be used as part of any REA by making this information accessible for 
HTA; thus, this ensures that this information will be available for all HTA agencies. 
 
However, a number of concerns were expressed with the Proposal. The Proposal is not clear about 
the true role and power of the Commission to shape and determine the final conclusion of any joint 
assessment (REA). More detail was designed to be included in the delegated and implementing acts, 
and this creates uncertainty. Due to the way that the Proposal was set out, the Commission could 
potentially be in a position of conflict of interest. As the Commission is responsible for issuing the 
marketing authorisations for centrally authorised products, the Commission will be in an awkward 
position to support payers if during HTA they question, or do not agree with, any part of the marketing 
authorisation process or decision.  
 
Whatever the current HTA model within a country, the Proposal will impact on individual countries, 
their methods of HTA evaluation and their HTA and pricing and reimbursement agencies. This is 
generally considered negatively by countries which have well established systems for HTA and would 
therefore like to preserve their well established HTA processes based on years of experience. 
Alternatively, less advanced countries may consider collaboration on HTA as an opportunity for 
learning, standardisation and sharing of work. There is concern that particular requirements, which 
are not yet known and will be established later, could upset existing national and well-functional HTA 
models through European legislation and possibly impact the quality of assessment and reduce the  
speed of well developed HTA organisations and systems [44]. 
 
There is also belief that transferring the authority to conduct comparative benefit assessments (i.e. 
REA) of medicinal products to a single body with a binding effect on Member States is a violation of 
primary law, and this could have severe consequences among national pricing authorities in ensuring 
the cost-effective (pricing) provision for their medicinal products. The Proposal is shifting part of the 
HTA process (REA) to a European institution, but the responsibility for the other domains, including 
the economic, social, legal, ethical and the organizational context, remain within national healthcare 
systems. The Proposal may well have a significant impact on national processes and national 
legislation, and the final Regulation will supersede all overlapping national legislation. This is a 
particular concern if undue pressure is placed on the body undertaking the initial (joint) assessment. 
We already see high prices for new cancer medicines, and those for orphan diseases, with often 
limited health gain due to pressures resulting from the emotive nature of these diseases [36, 46-52].  
 
One way forward is to have realistic price expectations especially with the low cost of goods (e.g. low 
cost for ingredients and manufacturing compared to price of the product on the market) of some new 
cancer medicines [53]. This follows increasing calls for moderation in the pricing of new cancer 
medicines for long term sustainability [54-56], with world-wide sales of medicines for cancer at 
$107billion globally in 2015 and rising with more than 500 companies actively pursuing new oncology 
medicines [57]. There is a similar situation for new medicines for orphan diseases with EURORDIS 
having as one of its key objectives that by 2025 there should be 3 to 5 times more therapies for rare 
diseases approved per year in Europe than currently; however, prices up to three to five times 
cheaper to enhance access and affordability [29]. We are also aware of the general considerations 
regarding issues of fairer pricing and valued based pricing as seen for instance with the WHO 
launching the ‘Fair Price Forum’ [58,59]. In addition, there are ongoing discussions with the WHO and 
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others to address concerns with the availability and affordability of medicines for patients with cancer 
[51,55]. 
 
Other major concerns with joint assessment include potential comparators for clinical effectiveness 
analyses, with different requirements and attitudes among Member States including the use of 
placebo [34,36,60]. Different standard treatments are available in different countries. Will the selected 
comparator(s) be treatments recommended in national, Pan-European or International clinical 
guidelines? Alternatively, will there be a consensus on the different medicines currently reimbursed 
among Member States? Different selections could appreciably impact on potential prices despite 
external reference pricing across Europe [61-64]. This can potentially be addressed with 
comprehensive REA information being used to improve deliberations regarding the potential value of 
a new technology, and hence potential prices.  
 
A concern emphasised by Kalo et al (2016) [65], and also shared by some of the authors of this 
paper, is that HTA roadmaps cannot be fully transferred among Central and Eastern European (CEE) 
countries, due to national peculiarities such as country size and gross domestic product per capita. In 
addition to technical factors, there are also ethical and cultural considerations for HTA, including 
major differences in social values, public health priorities and models of healthcare financing among 
CEE countries. The clinical part of HTA is crucial to prepare the economic models and a number of 
authors consider that these cannot be separated. Moreover, different health technologies may 
challenge moral or cultural values and beliefs, and their implementation may also have significant 
impact on people other than the patient. These are essential considerations for health policy, and are 
important considerations as the Proposal is debated and potentially implemented. 
 
The possible restriction on payers’ jurisdiction over the methodology for HTA, and the position that 
Member States cannot implement any updates to the evaluation without the permission of the 
Commission, caused major reservations among the authors. There is concern that the Proposal will 
be a way of stopping payers and their advisers from developing new methodologies, and will be a 
means for controlling the ‘fourth hurdle’. One of the major challenges for HTA has been how to adapt 
the methodology for HTA to consider evolving issues such as the uncertainty from conditional 
approval, the evolution of new methods of payment including MEAs, as well as consideration of the 
technical specificities of the products which are always developing, e.g. with the introduction of 
different advanced therapy medicinal products (ATMPs) including gene therapies [66-70]. If these 
restrictions also cover factors such as the choice of comparators, update of the evaluation with new 
clinical data, information from registries, information to fill the gaps and uncertainty for medicines 
authorised through conditional approval and observational data, or outcome based risk sharing data 
after the joint assessment, then the REA assessment will just be based on the original marketing 
authorisation information. Restrictions in the methodology of HTA may propagate and increase the 
gaps in knowledge and prevent payers from using evidence-based evaluation approaches particularly 
for emerging principles such as value-based pricing, price negotiations, and novel models for 
payment. With increasing use of a new medicine in clinical practice, new effectiveness data may show 
that a medicine is less efficacious than originally established [71]. Alternatively, initial safety concerns 
become less of an issue in clinical practice as seen with the TNF alpha inhibitors in rheumatoid 
arthritis and psoriasis following registry studies among countries to fully assess issues of infection and 
cancer in reality [52,72,73]. Payers already face great challenges to pay premium prices for new 
medicines with uncertain effectiveness due to a lack of data or immature data, lack of proven cost-
effectiveness, and concerns with the budget impact as seen with some new medicines for cancer and 
orphan diseases and lately ATMPs such as gene therapy [35,38,48,69], and this will intensify and will 
threaten the sustainability of national healthcare systems, given the number of new medicines in 
development. 
 
The Proposal stipulates that the joint assessment must be finalised at the same time as the marketing 
authorisation decision. A growing number of new medicines are being granted a marketing 
authorisation without data from randomised clinical trials and with approval being based on the results 
from non-randomised, single arm open trials. Real world data evidence (observational and registries) 
is increasingly welcomed based on actual outcomes rather than surrogate data [74]. Incomplete data 
from marketing authorisation decision could compromise the HTA especially if there is no clear link 
between the surrogate markers and long term patient outcomes [75-77]. 
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Once the legislation is approved, the position of the Member States in the power balance will change. 
Article 8 of the Proposal includes an obligation for Member States to inform the European 
Commission on how the HTA evaluation was undertaken as well as an obligation to inform on any 
changes. There will no doubt be considerable questioning by industry and by the Commission on the 
right of Member States to consider different and potentially new aspects of the evaluation during 
pricing and reimbursement decisions. For example, if payers would be restricted from defining unmet 
medical need according to their perspective and to consider the uncertainty in effectiveness during 
HTA evaluation, they could be blocked from including these considerations in their deliberations and 
negotiations.  
 
The Proposal advocates for greater involvement of patients and other stakeholders in decision 
making. Authors expressed different experiences with the involvement of patients, patient 
organisations, and other stakeholders. The authors generally considered patient participation 
positively as a means to increase buy-in, include the patient perspective, and for pointing out missing 
aspects when considering new medicines. On the other hand, there is the possibility that patient 
participation can put pressure on decision making. There are already examples where particular 
diseases have been treated differently from others in certain countries, leading to difficulties with 
equity in the allocation of limited resources [51]. This includes special funding schemes for the 
reimbursement of orphan diseases and cancer as well as higher cost per QALY considerations for 
new medicines in these disease areas [35,36,46,48,49]. There is also some concern that joint 
assessments might be used to put pressure on countries to reimburse certain medicines, where these 
medicines otherwise would not be reimbursed due to financial constraints. 
 
The ‘legal basis’ has been one of the main criticisms relating to the Proposal. TFEU sets the mandate 
for the pharmaceutical framework. Article 168 of the TFEU specifies that a high level of human health 
protection shall be ensured in the definition and implementation of all Union policies and activities 
Under Article 168(4) (c) of the TFEU, the European Parliament and the Council can, in order to meet 
common safety concerns, adopt measures setting high standards of quality and safety for medicinal 
products and devices for medical use. The main legal basis for the Proposal is the single market and 
not public health, in particular Article 114 of the TFEU, whose objective is the establishment and 
functioning of the internal market.  
 
5. Consolidation of other relevant opinions and recommendations from the authors  
 
Significant progress has been achieved in the agreement on joint standardised methodologies and 
tools through EUnetHTA and other recent EU-funded projects on HTA methodologies, including 
MedTecHTA and INTEGRATE-HTA, with education, establishing methodologies for medicinal 
products and medical devices, dealing with complex health technologies, as well as instigating new 
methods for assessment [78-80], and this work should be expanded.  
 
EUnetHTA identified that the processes of application for reimbursement are started at different times 
in different Member States, with different criteria for the level of evidence required by different 
European countries [79], thereby making further integration challenging. Other key issues, as 
mentioned, include consensus over comparators and treatment approaches [34]. If the Proposal were 
to specify the evaluation but factor out appraisal and comparison with treatments as well as their 
applicability (or external validity of the new pharmaceutical), this could compromise its applicability.  
 
The Proposal could improve collaboration between HTA bodies and payers, medicines regulators, 
and marketing authorisation holders (MAHs). Regulation (EC) No 726/2004 allows joint regulatory and 
HTA scientific advice for applicant MAHs at an early stage of development of a medicinal product, and 
this experience is generally considered positively [81]. However, there is currently a lack of 
collaboration between medicines regulation and HTA, as well as pricing and reimbursement 
authorities, in monitoring the effectiveness of new medicines during the post-authorisation phase, 
although this is increasingly happening at a national level [52,72,82-86]. With the introduction of 
conditional approvals, there is a shift in responsibility for effectiveness from the marketing 
authorisation to the post-authorisation phase [87], and this also brings added burden on the financing 
of new medicines by national healthcare systems.  
 
Regulators should clearly identify and document the gaps in data at the time of the marketing 
authorisation decision, and transparently include these requirements as part of the conditional 
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marketing authorisation approval, together with time-lines for presentation of this data for granting of a 
non-conditional approval. There have been challenges and concerns among some stakeholders with 
the current system for conditional approval. These include difficulties with delisting medicines from 
conditional schemes if their value is not shown in routine clinical practice [88], coupled with concerns 
with the strength of evidence at approval [89]. Regulators should enforce the requirements for non-
conditional approval and update the effectiveness data as part of variations to the marketing 
authorisation, including variations or withdrawal of marketing authorisation where lack of effectiveness 
becomes evident. There should also be similar activities among payers and companies if the value of 
the new medicine is not shown in routine clinical care.  
 
Currently the marketing authorisation holder collaborates with payers on reimbursement conditions 
and pricing through for instance MEAs and other mechanisms [41-43,90]. This collaboration could 
include consideration of conditions for the marketing authorisation holder to be able to collect the 
required effectiveness information for the granting of the non-conditional approval such as through the 
upkeep of registries with the increasing use of electronic health records [91], as well as initiatives 
such as GetReal, which is a three-year project involving the Innovative Medicines Initiative (IMI), 
pharmaceutical companies, academia, HTA agencies, payers, regulators, patient organisations as 
well as commercial organisations in generating patient level data [92]. Such collaborations will no 
doubt change the relationship between marketing authorisation holders and payers, and the power of 
each, during price negotiations and any update of prices. This should not be compromised.   
 
Overall, whilst the Proposal on HTA gives a framework for cooperation on REA, the Proposal 
specifies that details of the HTA process and methodology will come through the delegated acts and 
the implementing acts. Some authors are concerned with this. While the assessment for marketing 
authorisation of medicinal products is based on guidelines which are subject to interpretation, the HTA 
appraisal will be directed by a strict and detailed methodology imposed through legislation which will 
restrict the assessment process and adaptation. It will be difficult to keep updating this legislation with 
every change that is warranted. The experience of the Falsified Medicines Directive (Directive 
2011/62/EU) is a good example of how requirements set through legislation will be difficult to 
implement [93]. 
 
6. Opinions of the authors on the model for collaboration on HTA between Member States 
 
In spite of the efforts made by a number of Member States and the Commission, and the resources 
invested, Member States have not achieved the point where they effectively fully collaborate together 
on HTA voluntarily. Their approach is still typically country specific. This has made a legislative 
proposal seem the only remaining alternative to achieve full HTA collaboration among Member 
States. The experience of EUnetHTA has shown that Member States are not willing to cooperate 
voluntarily on HTA. However, there have been some initiatives for cross border and regional 
collaborations concerning key aspects of pricing and reimbursement in recent years.  
 
Within the current pharmaceutical framework, there are aspects which are considered to be within the 
jurisdiction and rights of specific stakeholders. Companies are considered to have full rights on the 
setting of prices for their new medicines, the right to set conditions for lack of transparency on prices 
and for negotiation of prices, and the right to refuse to get into joint price negotiation and MEAs with 
Member States at their discretion. The Proposal on HTA will impinge on none of these rights of the 
companies.  
 
Member States currently have jurisdiction over the HTA evaluation within their healthcare systems, as 
well as reimbursement decisions including managed entry agreements (within the framework of 
Directive 89/105/EEC). Currently Member States also have the right to decide to whether and how to 
collaborate between themselves on these activities. The Proposal will affect the level of voluntary 
collaboration on HTA. In the field of HTA, pricing and reimbursement, the Member States have 
considered and proposed Member State driven voluntary cooperation, and there have been the 
experiences of EUnetHTA, the HTA Network and regional cross border collaborations, all of which are 
voluntary. The cooperation stipulated in the Proposal follows a more coercive model.  There are 
divergent opinions between the authors regarding HTA cooperation regulated by legislation.  
 
In the field of medicines regulation, there are a number of Member State collaborations such as the 
role of Member States in the various procedures of the European Medicines Agency [94], which is 
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governed by Regulation (EC) No 726/2004, and the Heads of Medicines Agencies, which is a 
voluntary network of heads of the national competent authorities (NCAs) for medicines regulation [95].  
 
There are different models for the formation of networks and for international coordination. These 
arrangements may vary in complexity. Examples of such models include trans-national regulators 
setting ‘soft law’ standards, supra-national legal requirements, application of regulatory instruments, 
professional self-regulators and certification bodies. Coordination is a major challenge in such 
networks. Not all regulators will have the same substantive or normative conceptions of ‘good’. They 
also have varying capacity, skills and resources, and these differences are likely to affect their 
preferred approach to regulation as well as their responsiveness. Some regulators are flexible and 
able to cope with change and others are not. There are also differences in regulatory cultures, and 
these are reflected in regulatory interventions. Moreover, different regulators will occupy positions and 
status within the broader political and legal infrastructures and may be controlled by other 
governmental institutions [96]. There may be other factors and interests including sources of funding 
and financial governance of institutions. 
 
Baldwin et al. (2011) describe five different modes of coordination within government networks [96]. 
These are: 
 Hierarchies which involve a top-down arrangement in which a central body lays down rules and 
policies that provide direction to inferior institutions within the network.  
 The second mode is coordination of a network, whereby a stable group of peers engages in 
mutual recognition of membership and where there is sharing of a common set of interests.  
 A third approach to coordination is network management which involves a lead party or ‘manager’ 
body taking positive steps to facilitate concerted network actions by fostering collective behaviour 
through building levels of consensus to enable actions to be taken.  
 Distinctly, the fourth approach is based on rituals, which may be adopted voluntarily or imposed.  
 Fifthly, coordination can be left to markets, and is in the interests of participants who are willing to 
exchange resources and conclude agreements in order to attain mutually beneficial solutions and 
higher levels of collective welfare.  
 
EUnetHTA and the Regional Cooperations for HTA are most closely represented by the third 
approach, i.e. where there is a lead party and an organisation of initiatives under different leadership 
models. The Proposal on HTA as proposed by the Commission presents a hierarchical model (the 
first model), whereby the Commission will lay the rules and Member States will have to follow these 
(both for the assessment - REA - and the re-assessment). If this model is adopted, the legislation will 
‘force’ Member States to cooperate on the REA.  
 
Logically, it is difficult to understand how currently Member States have difficulties to fully cooperate 
voluntarily within EUnetHTA but could end up all happily and voluntarily coordinating together within a 
hierarchical model. Some Member States with limited capabilities, expertise and resources are very 
happy to collaborate in order to avoid issues such as duplication and to benefit from the resources of 
other countries [44]. We recognise though that within the network of voluntary cooperation, there are 
still elements of hierarchy and power struggle, and those who feel less strong may rather be at par 
with other Member States under a third party than feel “bullied“ by certain more powerful Member 
States. Ideally Member States should agree to cooperate between them in a framework which is set 
and managed by them. In the meantime, Member States could build on current cross border 
collaborations and other arrangements with existing co-operation around key activities such as 
horizon scanning as well as pricing and reimbursement considerations [15-18,97,98].  
 
7. Conclusions 
 
Currently, there are different opinions, perspectives and interests on the Proposal both within and 
between key stakeholder groups.  
 
There seems to be a high level of support for collaboration on HTA across Europe as collaboration 
increases the efficiency of HTA by avoiding duplication as well as maintaining or improving the quality 
of assessments. Alongside this, it is important to safeguard the needs of individual Member States 
and to take the local context into consideration. Success in producing European HTA’s of high quality 
which can be used by all Member States without compromising their healthcare systems can be a 
catalyst for further cooperation.  
11 
 
 
Payers may benefit from the possibility of regional cooperation for joint horizon scanning, 
negotiations, pricing and the possibility of transparency in pricing at their discretion. This is happening 
to a limited extent. Collaboration is considered to result in increased strength and negotiation power, 
which are especially important for new premium priced medicines. These are also key principles of 
the single market.  
 
A number of changes have been put forward by ENVI regarding proposed methodologies. The thrust 
of these are to make the process more transparent and expert-based. These are welcome 
developments [4]. However the idea to list the stakeholders to be consulted without mentioning 
payers in Amendments 33,75,108, 116, 121, 136 and 149 has been a major concern as payers 
typically have budget responsibility in their countries [5]. 
 
It is up to Member States to decide whether and how much the Proposal affects their jurisdiction over 
HTA and what the implications of the legislation would be. The Proposal is shifting the process of HTA 
outside national jurisdiction, but the responsibility for pricing and reimbursement remains among 
national healthcare systems. If Member States truly support the objective of increasing collaboration 
on HTA, they need to find a way for collaborating between them, preferably fully within their power.  
 
Once the Proposal is approved, then the Member States will need to embark on its implementation. A 
lot of good work has already been done, and this should be used as the foundation for future 
developments of HTA. In terms of working together and collaboration, much needs to be learnt and to 
be put into practice. If the Proposal is not approved through the co-legislative process, it is important 
that all that has been invested through EUnetHTA and other work, particularly the methodologies and 
tools which have been developed, as well as the consolidations which would have been attained 
through the discussions of the Proposal, are utilized to find the best way forward.  
 
The co-authors will be critically following the developments with the Proposal, and commenting on 
any future developments.  
 
8. Expert Commentary  
 
Thoughtful compromises and proactive ways forward highlighted in this paper are necessary to 
achieve a model for cooperation on HTA which will benefit all European citizens. This especially given 
the current considerable differences that exist between Member States in terms of issues of access 
and affordability of new medicines, including those for cancer and orphan diseases, which is likely to 
intensify with the launch of more complex technologies including gene therapies. Whichever model is 
finally decided upon, healthy discussion and debate regarding any Proposal is essential to enhance 
future support.  
 
If there is support for collaboration by a number of Member States, which is likely, then irrespective of 
the model chosen for collaboration, i.e. whether voluntary or through Regulation, there should be 
support by the Commission to make this model a success. This includes sufficient funds for any joint 
activities such as horizon scanning, assessment and other associated activities.  
 
9. Five year review 
 
There will be increased HTA collaboration across Europe over the next five years whether this is 
voluntary or governed by regulations. European countries will benefit in different ways from increased 
collaboration. Some will benefit more substantially than others addressing key issues such as 
availability of resources and personnel to fully undertake HTA evaluations. Methodologies will also 
improve as a result of joint collaborations, and there will be increased funding for joint research 
projects. 
 
However, it is likely that issues such as access, affordability and availability of medicines throughout 
European countries will remain in spite of collaboration on HTA due to continued differences in 
affordability between different European countries and the lack of impact of collaboration on HTA on 
the prices of medicines. 
 
10. Key Points 
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 There have been concerns with variable collaboration on health technology assessments (HTA) 
among European countries, as well as use of assessments from European groups, despite a 
number of initiatives over twenty years across Europe to address this. 
 With current funding coming to an end, the European Commission has published a Proposal for 
joint assessments of HTA incorporating Relative Effectiveness Assessments (REAs) to address 
these concerns. 
 Some benefits of collaboration on HTA include reduced duplication, improved efficiency and 
improved quality of evaluation, particularly for countries with limited national resources.  
 There are concerns with the Proposal including adequately addressing issues of different 
methodologies, tools and models for HTA across Europe, the potential binding of assessments 
and restrictions with adopting methodologies for HTA which address issues such as the lack of 
evidence following marketing authorisation and uncertainty,  
 The Proposal has generated ongoing debate and a great deal of alternative considerations in an 
attempt to achieve an agreed position. This will continue 
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